{"entity":{"id":"vt3989","kind":"drug","name":"VT3989","aka":[],"tldr":"VT3989 is an experimental pill from Vivace Therapeutics, in phase 2 trials for mesothelioma.","summary":"VT3989 is a small molecule, oral from Vivace Therapeutics. Stops TEAD transcription factors in the Hippo pathway from attaching a fatty acid to themselves (autopalmitoylation), which they need to drive cancer cell growth. Its phase 1/2 study (NCT04665206) is recruiting people with solid tumours, mesothelioma and non-small cell lung cancer; a phase 3 study in pleural mesothelioma (NCT07824986) is registered and not yet recruiting. TEAD has no target record in OnCo.","status":"phase-2","asOf":"2026-11-04","links":[{"label":"Vivace Therapeutics Series D release, March 2025","url":"https://www.biospace.com/press-releases/vivace-therapeutics-raises-35-million-in-series-d-financing-to-support-clinical-development-of-first-in-class-cancer-drug-targeting-the-hippo-pathway"},{"label":"ClinicalTrials.gov NCT04665206","url":"https://clinicaltrials.gov/study/NCT04665206"},{"label":"ClinicalTrials.gov NCT07824986","url":"https://clinicaltrials.gov/study/NCT07824986"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mesothelioma","pleural-mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["vivace-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04665206","nct07824986"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"VT3989","modality":"Small molecule, oral","mechanism":"Stops TEAD transcription factors in the Hippo pathway from attaching a fatty acid to themselves (autopalmitoylation), which they need to drive cancer cell growth.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vt3989/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/"}],"company":[{"id":"vivace-therapeutics","kind":"company","name":"Vivace Therapeutics","route":"/companies/vivace-therapeutics/"}],"trial":[{"id":"nct07824986","kind":"trial","name":"A Phase 3 Trial in Advanced Epithelioid Mesothelioma","route":"/trials/nct07824986/"},{"id":"nct04665206","kind":"trial","name":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","route":"/trials/nct04665206/"}]}}